食管癌 在华治疗

中国自主研发的PD-1药物已用于食管鳞状细胞癌：卡瑞利珠单抗已在中国获批该适应症，替雷利珠单抗（tislelizumab）则已获FDA批准（2024年、2025年）。中国还于2026年批准了satri-cel CAR-T，用于Claudin18.2阳性的胃食管交界腺癌。患者可通过医院肿瘤科或临床试验获得治疗。
已核验最后核验

可用疗法

可用疗法在华状态在美状态信息来源
Camrelizumab (PD-1) for esophageal squamous cell carcinoma在中国已获批未获批
Tislelizumab (Tevimbra) for ESCC未知在中国已获批Elevar Therapeutics / GlobeNewswireU.S. FDA
Satri-cel (Claudin18.2 CAR-T) for gastric/GEJ adenocarcinoma after two prior lines在中国已获批未获批U.S. FDA

有公开项目的医院

以下为有来源的公开信息，不构成推荐。

Xuhui campus of Fudan University Shanghai Cancer Center (复旦大学附属肿瘤医院) on Dong'an Road, with the hospital name on the main tower
Shanghai复旦大学附属肿瘤医院Fudan University Shanghai Cancer CenterInternational deptReported
Name plaque at the entrance of Zhejiang Cancer Hospital, Hangzhou
Hangzhou浙江省肿瘤医院（中国科学院大学附属肿瘤医院）Zhejiang Cancer Hospital (Cancer Hospital of the University of Chinese Academy of Sciences)No public intl deptVerified
Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center) (中国医学科学院肿瘤医院) building exterior
Beijing中国医学科学院肿瘤医院Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center)No public intl deptVerified
Peking University Cancer Hospital (Beijing Cancer Hospital) (北京大学肿瘤医院) building exterior
Beijing北京大学肿瘤医院Peking University Cancer Hospital (Beijing Cancer Hospital)No public intl deptVerified
Sun Yat-sen University Cancer Center (中山大学肿瘤防治中心) building exterior
Guangzhou中山大学肿瘤防治中心Sun Yat-sen University Cancer CenterInternational deptVerified

临床试验

234项研究正在中国招募（ClinicalTrials.gov，截至 2026-10-26）. 查看列表

我们只提供试验链接；是否入组由试验团队决定。据 AFP 报道，自 2026 年 5 月起中国禁止向患者收取临床研究费用。

常见问题

替雷利珠单抗是否获FDA批准用于食管癌？

是的。FDA于2024年3月14日批准其用于既往治疗过的不可切除或转移性食管鳞癌，并于2025年3月3日批准其联合化疗用于PD-L1表达≥1的一线治疗。

[1] U.S. FDA[2] U.S. FDA

satri-cel是否适用于食管癌？

根据2026年6月国家药监局的批准，仅适用于Claudin18.2阳性、HER2阴性且既往至少接受过两线治疗的胃食管交界腺癌，不覆盖鳞状细胞癌。

[1] CARsgen Therapeutics

信息来源

  1. Elevar Therapeutics Receives FDA Complete Response Letter for rivoceranib plus camrelizumab in HCC
    Elevar Therapeutics / GlobeNewswire · official · accessed 2026-10-26
    “Camrelizumab is currently approved for eight indications in China, including relapsed/refractory classic Hodgkin's lymphoma (third-line) and esophageal squamous cell carcinoma.”
  2. Drug Trials Snapshots: TEVIMBRA
    U.S. FDA · official · accessed 2026-10-26
    “TEVIMBRA (tislelizumab-jsgr), BeiGene, approval date: March 14, 2024, for esophageal squamous cell carcinoma after prior chemotherapy.”
  3. Tevimbra BLA 761380 approval letter (first-line ESCC, PD-L1 >=1)
    U.S. FDA · official · accessed 2026-10-26
  4. CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
    CARsgen Therapeutics · official · accessed 2026-10-26
    “Satri-cel is the world's first approved CAR T-cell therapy product for the treatment of solid tumors.”

本站仅提供信息，不构成医疗建议、诊断或治疗推荐。请咨询你的医生。紧急情况请立即拨打当地急救电话。